Intellia Therapeutics Inc
Closed
SectorHealthcare
11.31 5.11
Overview
Share price change
24h
Min
10.75
Max
11.33
Income | 106M -96M |
|---|---|
Sales | -8M 15M |
EPS | -0.81 |
Profit margin | -639.494 |
Employees | 377 |
EBITDA | 1.4M -94M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +75.67% upside |
Next Earnings | 6 sie 2026 |
|---|
Market Cap | -145M 1.5B |
|---|---|
Previous open | 6.2 |
Previous close | 11.31 |
Intellia Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Intellia Therapeutics Inc Forecast
Price Target
By TipRanks
75.67% upside
12 Months Forecast
Average 18.92 USD 75.67%
High 49 USD
Low 8 USD
Based on 14 Wall Street analysts offering 12 month price targets forIntellia Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
